Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

18
How much is too much?

2018-06-30 theedgemarkets
Board of director (BOD) and CEO compensation is a divisive topic even in normal times. How much is too much? What is the right compensation relative to performance?
PNADF 5347 5183 1368 PECGF TNABY 5681 TNABF BSMAF PNAGF 6033 1818

2
AWC seen likely to complete Trackworks stake acquisition

2018-06-21 theedgemarkets
AWC Bhd (June 20, 63 sen) Maintain add with a target price of RM1.00: We gather that AWC Bhd expects its integrated facilities management (IFM) segment to continue to perform strongly, given better economies of scale, increase in order book, and higher recognition from its Critical Asset Refurbishment Programme (CARP). CARP is a 10-year programme (January 2016 to December 2025) for the replacement of old mechanical and electrical equipment at government buildings at a pre-agreed schedule.
1368

2
Trading ideas: Econpile, UEM Edgenta, MyEG

2018-06-04 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Econpile Holdings Bhd , UEM Edgenta Bhd and MyEG Services Bhd to be among the stocks to watch on Monday following their latest corporate news.
1368 5253

2
UEM Edgenta bags RM60.7mil consulting job for Pan Borneo Sabah highway project

2018-06-01 thestar.com.my
KUALA LUMPUR: UEM Edgenta Bhd wholly owned unit Opus International (M) Bhd has been appointed by Borneo Highway PDP Sdn Bhd as the lead consultant to provide pavement design support for the Pan Borneo Highway Sabah project.
1368

5
Trading ideas: Construction stocks, Eduspec, Benalec, UEM Edgenta, PPB

2018-05-14 thestar.com.my
KUALA LUMPUR: JF Apex Research expects construction stocks, Eduspec holdings Bhd , Benalec Holdings Bhd, UEM Edgenta Bhd and PPB Group Bhd to be among the stocks to watch on Monday.
5190 1368 4065

2
UEM Edgenta to invest RM40mil in technology

2018-05-10 thestar.com.my
PETALING JAYA: UEM Edgenta Bhd has set aside about RM40mil this year to invest in various technology platforms as part of efforts to improve margin and save costs by between 20% and 30%.
1368

6
UEM Edgenta adopts higher dividend policy

2018-05-09 thestar.com.my
It is higher than the previous dividend policy payout ratio of up to 70%, the total asset solutions provider said in a filing with Bursa Malaysia.
1368 BSMAF 1818

2
UEM Edgenta boosts dividend payout policy

2018-05-08 thestar.com.my
KUALA LUMPUR: UEM Edgenta Bhd has announced a higher dividend payout policy with effect from financial year ending Dec 31, 2018.
1368

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...